Morning Movers 07/18: (SUPN) (GALE) (AIR) (APH) Higher; (ROVI) (WHX) (HHS) Lower
Tweet
Share
E-mail
Get Alerts ROVI Hot Sheet
Join SI Premium – FREE
Rovi Corporation (Nasdaq: ROVI) 40.9% LOWER; sees Q2 EPS of $0.35-$0.38, vs $0.57. Revenues $158-$179 million, versus the consensus of $182.6 million. The stock was downgraded at BMO, Piper Jaffray, JPMorgan, Barrington and Cowen this morning.
Supernus Pharma (Nasdaq: SUPN) 23.8% HIGHER; gapped over resistance at $11, quickly charged through the $12 level, and has now moved over $13. Volume is very heavy this morning.
Galena Biopharma, Inc. (Nasdaq: GALE) 19.4% HIGHER; was issued a key patent, originally allowed in March 2012, from the USPTO covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH rating of less than 2.0.
Whiting USA Trust I (NYSE: WHX) 19.2% LOWER; shares continuing lower after failing to push over the 50-day simple moving average a number of times yesterday. The stock fell more than 9 percent yesterday. Shares plunged through support at $14 this morning.
Harte-Hanks, Inc. (NYSE: HHS) 16.5% LOWER; sees Q2 sales of $195-$205 million and EPS of 10-12 cents. The Street is looking for revs of $208.9 million and EPS of $0.16. Sees a Q2 non-cash pre-tax charge of $150-$177 million. Click here to see the full report.
AAR Corp. (NYSE: AIR) 15.9% HIGHER; reported Q4 EPS of $0.45, $0.01 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $563.3 million versus the consensus estimate of $562.3 million. AAR Corp. reaffirmed FY2012 guidance.
Amphenol, Inc. (NYSE: APH) 14.5% HIGHER; reported Q2 EPS of $0.79, $0.05 worse than the analyst estimate of $0.84. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion. Sees Q3 sales of $1.08-$1.1 billion, which compares to the Street estimate of $1.06 billion. Sees EPS of 87-90c, vs. the consensus of 85c.
VIVUS, Inc. (Nasdaq: VVUS) 14% HIGHER; the FDA approved VIVUS's weight-loss drug Qsymia (Qnexa) as added reduced-calorie diet pill, according to Bloomberg headlines.
Anthera Pharma (Nasdaq: ANTH) 11.3% LOWER; investors are taking profits following a 125 percent rally over the last two trading sessions. On Monday the company announced positive data related to its Phase 2b PEARL-SC trial.
Aruba Networks (Nasdaq: ARUN) 10.8% HIGHER; the Networking sector is on fire this morning following notable downside over the last two and a half months. Shares of Aruba had fallen as much as 41 percent since the beginning of May.
Flagstar Bancorp, Inc. (NYSE: FBC) 10.1% HIGHER; reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01.
Amicus Therapeutics (Nasdaq: FOLD) 9.6% HIGHER; and Glaxo Group Limited (NYSE: GSK) announced an expansion of their collaboration to develop and commercialize the investigational pharmacological chaperone migalastat HCl for Fabry disease.
EMC (NYSE: EMC) 9% HIGHER; see below for exec change news. EMC sees Q2 consolidated revenues of approximately $5.31 billion, up 10% over Q2 2011, and record Q2 non-GAAP earnings per weighted average diluted share (EPS) of $0.39, up 11% over Q2 2011. The Street was looking for revs of $5.29 billion and EPS of $0.40. EMC continues to expect to achieve its full-year 2012 goals of $22 billion in revenue and non-GAAP EPS of $1.70. The Street sees FY12 revs of $22.1 billion and EPS of $1.73.
Supernus Pharma (Nasdaq: SUPN) 23.8% HIGHER; gapped over resistance at $11, quickly charged through the $12 level, and has now moved over $13. Volume is very heavy this morning.
Galena Biopharma, Inc. (Nasdaq: GALE) 19.4% HIGHER; was issued a key patent, originally allowed in March 2012, from the USPTO covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH rating of less than 2.0.
Whiting USA Trust I (NYSE: WHX) 19.2% LOWER; shares continuing lower after failing to push over the 50-day simple moving average a number of times yesterday. The stock fell more than 9 percent yesterday. Shares plunged through support at $14 this morning.
Harte-Hanks, Inc. (NYSE: HHS) 16.5% LOWER; sees Q2 sales of $195-$205 million and EPS of 10-12 cents. The Street is looking for revs of $208.9 million and EPS of $0.16. Sees a Q2 non-cash pre-tax charge of $150-$177 million. Click here to see the full report.
AAR Corp. (NYSE: AIR) 15.9% HIGHER; reported Q4 EPS of $0.45, $0.01 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $563.3 million versus the consensus estimate of $562.3 million. AAR Corp. reaffirmed FY2012 guidance.
Amphenol, Inc. (NYSE: APH) 14.5% HIGHER; reported Q2 EPS of $0.79, $0.05 worse than the analyst estimate of $0.84. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion. Sees Q3 sales of $1.08-$1.1 billion, which compares to the Street estimate of $1.06 billion. Sees EPS of 87-90c, vs. the consensus of 85c.
VIVUS, Inc. (Nasdaq: VVUS) 14% HIGHER; the FDA approved VIVUS's weight-loss drug Qsymia (Qnexa) as added reduced-calorie diet pill, according to Bloomberg headlines.
Anthera Pharma (Nasdaq: ANTH) 11.3% LOWER; investors are taking profits following a 125 percent rally over the last two trading sessions. On Monday the company announced positive data related to its Phase 2b PEARL-SC trial.
Aruba Networks (Nasdaq: ARUN) 10.8% HIGHER; the Networking sector is on fire this morning following notable downside over the last two and a half months. Shares of Aruba had fallen as much as 41 percent since the beginning of May.
Flagstar Bancorp, Inc. (NYSE: FBC) 10.1% HIGHER; reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01.
Amicus Therapeutics (Nasdaq: FOLD) 9.6% HIGHER; and Glaxo Group Limited (NYSE: GSK) announced an expansion of their collaboration to develop and commercialize the investigational pharmacological chaperone migalastat HCl for Fabry disease.
EMC (NYSE: EMC) 9% HIGHER; see below for exec change news. EMC sees Q2 consolidated revenues of approximately $5.31 billion, up 10% over Q2 2011, and record Q2 non-GAAP earnings per weighted average diluted share (EPS) of $0.39, up 11% over Q2 2011. The Street was looking for revs of $5.29 billion and EPS of $0.40. EMC continues to expect to achieve its full-year 2012 goals of $22 billion in revenue and non-GAAP EPS of $1.70. The Street sees FY12 revs of $22.1 billion and EPS of $1.73.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- AptarGroup (ATR) Tops Q1 EPS by 11c
- COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Piper Jaffray, JPMorgan, Cowen & Co, Morning Movers, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
